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We report that like other T cells cultured in the presence of transforming growth factor
(TGF) , Th17 cells also produce interleukin (IL) 9. Th17 cells generated in vitro with IL-6
and TGF- as well as purified ex vivo Th17 cells both produced IL-9. To determine if IL-9
has functional consequences in Th17-mediated inflammatory disease, we evaluated the
role of IL-9 in the development and progression of experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis. The data show that IL-9 neutralization and
IL-9 receptor deficiency attenuates disease, and this correlates with decreases in Th17 cells
and IL-6–producing macrophages in the central nervous system, as well as mast cell numbers in the regional lymph nodes. Collectively, these data implicate IL-9 as a Th17-derived
cytokine that can contribute to inflammatory disease.
CORRESPONDENCE
Randolph J. Noelle:
rjn@dartmouth.edu
Abbreviations used: CNS, central nervous system; EAE, experimental autoimmune
encephalomyelitis; MC, mast
cell; MOG, myelin oligodendrocyte peptide; qRT-PCR,
quantitative real-time PCR.

CD4 T cells have been divided into several subsets as defined by their cytokine products and
functions after their activation. These include,
but are not limited to, Th1, Th2, and Th17
cells. The initial two T cell subsets described
were Th1 cells, which secrete IFN- and aid in
the clearance of intracellular bacteria and viruses,
and Th2 cells, which secrete IL-4 and IL-5 and
help control extracellular pathogens. More recently, Th17 cells have been described as a third
Th cell type that express the transcription factor
RORt and IL-17A, provide protection against
fungi and various other extracellular bacteria,
and are pathogenic T cells in the development
of autoimmune inflammatory diseases (Zhu and
Paul, 2008).
Discovery of the T cell subsets that produce
IL-9 has expanded significantly in recent years.
IL-9 was primarily studied as a product of Th2
cells, and implicated as an important regulatory cytokine in the lung and the gastrointestinal tract (Faulkner et al., 1997; Townsend et al.,
2000; Forbes et al., 2008). Schmitt et al. first
reported that IL-9 production is dependent on
the initial presence of IL-2, and is greatly increased by the addition of TGF- in a dosedependent manner. They also observed that
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the addition of IL-4 to TGF- in T cell cultures substantially enhanced T cell IL-9 production (Schmitt et al., 1994). This finding has
been recently reexamined by two groups who
suggest that the T effector cells produced by
TGF- and IL-4 may represent a unique subset of T cells, as these cells do not express any
of the known transcription factors for T cell
differentiation, including T-bet, GATA-3,
RORt, and FoxP3 (Dardalhon et al., 2008;
Veldhoen et al., 2008). More recent work has
shown that T cell–derived IL-9 may mediate
immunosuppression. Adaptive T reg cells derived from encephalogenic T cells produce IL-9
(Liu et al., 2006), and our own studies have
shown that IL-9 can be colocalized with T reg
cells within the tolerant allograft and is functionally important for allograft survival (Lu
et al., 2006). Therefore, IL-9 is produced by
T cells that play a role in both inflammation
and immunosuppression.
In this report, the hierarchy of IL-9 production by defined T cell subsets was compared.
© 2009 Nowak et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months
after the publication date (see http://www.jem.org/misc/terms.shtml). After six
months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons
.org/licenses/by-nc-sa/3.0/).
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To unequivocally address IL-9 production by Th17 cells,
IL-17F reporter T cells were used and demonstrated IL-9
production by purified Th17 cells. Given this observation,
it was determined whether IL-9 played a functionally significant role in the Th17-mediated disease experimental autoimmune encephalomyelitis (EAE). The data show that IL-9
neutralization and IL-9R deficiency attenuate disease, and
this correlates with decreases in Th17 cells and IL-6–producing macrophages in the central nervous system (CNS), as
well as mast cell (MC) numbers in the regional lymph nodes.
Collectively, these data implicate IL-9 as a Th17-derived
cytokine that can contribute to inflammatory disease.
RESULTS AND DISCUSSION
Th17 cells produce IL-9
To confirm the observation of Schmitt et al. (1994) that
TGF- can induce IL-9 production, we stimulated T cells
with the indicated concentrations of TGF- and assessed their
capacity to produce IL-9 after restimulation. As expected, we
saw that TGF- can induce IL-9 expression in a dose-dependent manner (Fig. 1 A). To further characterize IL-9 production by various T cell subsets, cells were cultured under defined
conditions known to induce a spectrum of T cell phenotypes.
The data show that Th17 (TGF- + IL-6) cells and cells
stimulated with TGF- + IL-4 produced similar amounts of
IL-9 (Fig. 1 B). As previously reported, it is also shown that
conditions that induce the differentiation of adaptive T reg
cells (TGF- + IL-2) generate T cells that produce IL-9. Because the cells differentiated under adaptive T reg cell conditions contain both Foxp3 and Foxp3+ T cells, Foxp3 reporter
T cells were used to sort-purify both of these populations to
determine their capacity to produce IL-9. The data show that
both of these populations produce similar amounts of IL-9
(Fig. 1 C). In general, the hierarchy of IL-9 production by
the conditions prescribed in these studies suggests that adaptive T reg cells consistently produced more IL-9 than Th2 cells
but less than cell-cultured T cells derived with TGF- and
IL-4 or IL-6 (Th17).
Heterogeneity in T cell differentiation is inherent in the
induction of adaptive T reg as well as Th17 cells. As had been
executed with the adaptive T reg cell studies, T cells from
IL-17F–Thy1.1 reporter mice (Lee et al., 2009) were cultured
with TGF- + IL-6 and Th17 purified by magnetic sorting
for Thy1.1. Because none of the existing monocloncal antibodies to mouse IL-9 are suitable for assessing cytoplasmic
fluorescence (Veldhoen et al., 2008), an IL-9 ELISA was used
to determine IL-9 production. The data show that the IL-17F–
positive population (>95% Th17 cells) produced IL-9 after
restimulation. Furthermore, the IL-17F–negative population
(<1% Th17 cells) produced fourfold less IL-9 than the IL-17F–
positive population (Fig. 1 D). We have also performed this
experiment an additional time using FACS sorting to obtain
purities of >99% for both populations with similar results
(unpublished data). To additionally confirm that IL-9 production by Th17 is not solely an in vitro phenomenon, we
also used FACS sorting of cells from RORC-GFP mice,
1654

which have been previously described to report the expression of RORt (Ivanov et al., 2006), and IL-17F–Thy1.1 mice.
As shown, after RORC-GFP mice receive a CFA immunization, we see a significant amount of IL-9 production from
these cells ex vivo as compared with an internal negative control
of naive T cells from the same mice (Fig. 1 E). We also performed the same experiment in IL-17F–Thy1.1 reporter
mice with similar results. In addition, we further sorted IL-17F–
negative CD44hi T cells from these mice and observed that
their capacity to produce IL-9 was less than the IL-17F–positive
CD44hi T cells (Fig. S1).
In addition to IL-9 secretion, the expression of IL-9R was
also evaluated on T cells. Previous work has extensively described IL-9 as influencing MCs and macrophages; however,
there are reports that its receptor is also expressed on effector but
not naïve T cells (Cosmi et al., 2004; Knoops and Renauld,
2004). As no monoclonal antibodies have been produced to
mouse IL-9R, all of these data are based on mRNA expression profiling. To confirm and expand these results, quantitative real-time PCR (qRT-PCR) was performed to quantify
IL-9R mRNA in T cells skewed under Th1, Th2, and Th17
conditions. The data show that Th2 and Th17 cells consistently had the highest expression of IL-9R mRNA expression, whereas Th1 cells had minimal expression (Fig. 1 F).
Thus, because of the fact that IL-9R is expressed on IL-9–
producing T cells, an autocrine impact of IL-9 on T cell differentiation is possible.
IL-9 neutralization ameliorates EAE
EAE is one disease model in which Th17 cells are the principle mediators of the symptoms observed. To determine if IL-9
contributes to Th17-mediated disease development, chronic
EAE was induced in mice with myelin oligodendrocyte peptide (MOG)35-55, CFA, and pertussis toxin while administrating either control Ig antibody or neutralizing IL-9 antibody
beginning the day before immunization. IL-9 blockade consistently delayed the onset of disease, and this difference was
statistically significant. However, mice did ultimately succumb
with the same disease severity as controls (Fig. 2 A).
Next, to determine if IL-9 blockade qualitatively altered the
T cell response to MOG, T cell responses were monitored during disease development. Mice were sacrificed at day 12 after
the initial immunization, at which point all mice showed little
or no signs of disease. At that time, CD4 T cells were purified
from the peripheral lymph nodes. Upon analysis, no significant
difference in MOG-specific IL-17A (Fig. 2 B) responsiveness
by ELISPOT was observed. However, MOG-specific IL-9
production was significantly enhanced in IL-9–treated mice
(Fig. 2 C), suggesting a possible feedback enhancement of IL-9
production caused by IL-9 blockade.
To assess the immune response in the CNS, qRT-PCR
on spinal cord samples from naive mice, EAE mice treated
with control Ig, and EAE mice treated with IL-9 antibody
was performed (Fig. 2 D). The data show a consistent decrease
in both IL-17A and IL-6 signals in the IL-9–treated mice but
no effect on IFN-. These data suggest that IL-9 blockade
IL-9, TH17, AND EAE | Nowak et al.
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preferentially attenuates Th17 responses. In addition, no difference in the mRNA expression of Ebi3, IL-10, IL-12a
(p35), or IL-12 (p40) was observed (unpublished data).
IL-9R deficiency impairs multiple aspects of disease
The data show that IL-9 blockade delays the induction of
EAE; however, these mice eventually progress to a similar
extent as controls. To independently evaluate the role of
IL-9, the development of EAE in IL-9R KO mice was evaluated. IL-9R KO mice had delayed onset of disease, similar to

what was observed with neutralizing antibody. However,
IL-9R–deficient mice consistently had decreased severity
over time and this difference was statistically significant. This
suggests IL-9 may exert an effect throughout the progression
of disease (Fig. 3 A).
Because the initial priming of Th17 cells in IL-9–treated
mice appears equivalent to controls in lymph node but decreased in the CNS, we sought to determine if the delay in
disease severity in IL-9R–deficient mice may be caused by
a decreased ability to traffic into the CNS. Recently, two

Figure 1. Th17 cells produce IL-9. (A) T cells were stimulated in vitro with the indicated concentration of TGF- for 4 d. Cells were washed, counted,
and restimulated in the presence of CD3/CD28 for 24 h before supernatants were collected for ELISA. Results show means ± SD of two independent
experiments. (B) Effector T cells were generated in vitro under the indicated conditions for 4 d and were restimulated as in A. Results are representative of
at least four independent experiments. (C) Cells from TGF- + IL-2 cultures were sorted based into FoxP3-GFP–positive and –negative subsets and
restimulated as in A. Results are representative of four independent experiments. (D) T cells cultured under Th17 conditions were separated into IL-17F–
positive and –negative subsets based on Thy1.1 expression using MACS columns (percentages are shown). Representative purity of both populations is
shown. Cells were restimulated as in A for IL-9 production. Results were pooled from two independent experiments, and a Student’s t test was performed
to compare the samples. Means ± SD are shown. (E) RORC-GFP mice were immunized with MOG emulsified in CFA, and splenic T cells were harvested 7 d
later for sorting into the indicated populations (percentages are shown). Cells were restimulated with PMA/ionomycin for 4 h before supernatant was
collected for ELISA. Results show means ± SD of two independent experiments, and a Student’s t test was performed to compare the samples. (F) qRT-PCR
from Th1, Th2, and Th17 cells and BM-MCs was performed for IL-9R expression. All samples were standardized to the expression of IL-9R by BM-MCs.
Results are representative of three independent samples from each experimental group.
JEM VOL. 206, August 3, 2009
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groups have highlighted the importance of CCR6 expression
during the initiation of EAE (Liston et al., 2009; Reboldi
et al., 2009); therefore, we examined T cell responses in the
lymph node on day 7 after immunization. In this case we
consistently found that the initial induction of CCR6 is
equivalent between WT and KO mice (Fig. 3 C). In addition, at late time points histochemistry performed on spinal
cord samples indicated that lymphocyte infilitrates were also
equivalent between these two groups (Fig. 3 B). This suggests that IL-9 responsiveness is not necessary for trafficking
of cells to the CNS.
To further characterize the immune response in the CNS
as well as to determine the cellular sources of IL-17A and IL-6
observed by qRT-PCR in IL-9–treated mice, flow cytometry was performed on isolated lymphocytes from the brain
and spinal cord of diseased WT and IL-9R KO mice. No
significant difference in the total numbers of infiltrating lym-

phocytes was observed by CNS cell isolation. However, the
numbers of IL-17A+ CD4 T cells and IL-6+ macrophages in
the CNS were decreased in IL-9R KO mice (Fig. 4, A and B).
In addition, IFN- responses were not significantly different
between groups (unpublished data).
It has been reported that MC deficiency can decrease the
severity of EAE (Secor et al., 2000), and that MC accumulation in the regional lymph nodes accompanies disease development (Tanzola et al., 2003). Given the fact that IL-9 is a
growth and differentiation factor of MCs (Zhou et al., 2001),
MC accumulation in immunized WT and IL-9R KO mice
was determined during the development of EAE. First, there
are no defects in MC numbers in naive IL-9R KO mice
(Steenwinckel et al., 2007). Second, WT EAE-immunized
mice had elevated MC numbers (Brenner et al., 1994). Third,
no MC accumulation was observed in immunized IL-9R
KO mice (Fig. 4 C). Hence, it appears that IL-9 is critical for

Figure 2. Treatment with neutralizing anti–IL-9 antibody slightly delays EAE. (A) Mice were immunized for EAE and were treated with control Ig
(n = 6) or IL-9 antibody (n = 6) i.p. every other day starting with day 1. Mice were scored for disease severity, and the mean ± SEM for each time point
is indicated. Results are representative of three independent experiments. The p-value obtained by a Mann-Whitney U test is indicated. (B and C) CD4
T cells from the peripheral lymph nodes of EAE-immunized mice were taken from each group at day 12 (score = 0 or 1 for all mice used) and stimulated
with antigen-presenting cells and MOG for (B) IL-17A spot-forming units (SFU) in ELISPOTs or (C) IL-9 concentration in ELISA. Means ± SD are shown for
both graphs. *, P < 0.05 from the control sample by a Student’s t test. Results shown are pooled from three independent experiments. (D) RNA was made
from spinal cord samples of EAE-immunized mice from each group at the peak of disease severity in control mice, and the mean expression relative to
-actin is shown. Results are representative of four naive, eight control, and eight IL-9–treated mice taken from three independent experiments.
1656
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the inflammation-induced accumulation of MCs during disease development.
A functional role for IL-9 in encephalitogenic T cells
was sought because differentiated Th17 cells express IL-9R
mRNA. As such, adoptive transfer studies were performed
using WT or IL-9R KO MOG-primed T cells. Furthermore, adoptive transfer of WT T cells into WT or IL-9R
KO hosts was performed to address whether host expression of IL-9R was important to the development of disease
(Fig. 4). The transfer of IL-9R KO T cells → WT and WT
T cells → IL-9R KO hosts caused a slight delay in disease
onset and reduced severity at early time points, but the mice

Figure 3. IL-9R deficiency ameliorates the severity of EAE. (A) WT
(n = 20) and KO (n = 21) mice were immunized for EAE and scored to generate graphs of mean disease score ± SEM. Results were pooled from three
independent experiments, and a Mann-Whitney U test was performed to
assess the p-value shown. (B) Transverse spinal cord sections of WT (n = 8)
and KO (n = 8) mice from two independent experiments were taken to
perform the hematoxylin and eosin staining shown. Bar, 200 µm. (C) On
day 7 after EAE immunization, draining lymph nodes of WT and KO mice
were taken and CD4 T cells were assessed for CD44 and CCR6 expression
(percentages are shown). Results are representative of three independent
experiments with four to six mice from each group per experiment.
JEM VOL. 206, August 3, 2009

eventually succumbed to the same extent as WT T cells →
WT controls. However, the transfer of IL-9R KO T cells
→ IL-9R KO hosts displayed both delayed onset and reduced severity of disease. Overall, these results suggest that
IL-9R expression on both the encephalitogenic T cells and
other host cell types contributes to the effect seen in IL-9R
KO mice.
The findings presented establish (a) the hierarchy of IL-9
production by differentiated T cell subsets and purified subsets
derived from these cells, (b) that purified Foxp3+ adaptive T
reg and Th17 cells produce IL-9, (c) that IL-9 contributes to
the development of EAE, (d) that IL-9 influences the expression of IL-17A and IL-6 in the CNS, and (e) that IL-9 mediates
the accumulation of MCs in the regional lymph nodes during
the development of EAE. Collectively, the findings implicate
IL-9 as a mediator of Th17-driven inflammatory diseases.
The data show that both Th17 and TGF- + IL-4 T cells
produce high levels of IL-9 upon restimulation. Furthermore,
Foxp3+ and Foxp3 T cells from in vitro generation of adaptive T reg cells also produce IL-9. To definitively show that
Th17 cells produce IL-9, reporter Th17 cells were isolated
and IL-9 production was confirmed. These results add to the
growing list of IL-9–producing T cells, which includes natural T reg, adaptive T reg, and Th2 cells (Gessner et al., 1993;
Schmitt et al., 1994; Hauber et al., 2004; Liu et al., 2006; Lu
et al., 2006). In contrast, Veldhoen et al. (2008) reported that
neither Th2, adaptive T reg, natural T reg, nor Th17 cells
produce IL-9. The differences between that study and the
findings in this paper, as well as others (Gessner et al., 1993;
Schmitt et al., 1994; Hauber et al., 2004; Liu et al., 2006; Lu
et al., 2006), has yet to be resolved.
In addition, the data show that IL-9 blockade by antibody
or by IL-9R deficiency can ameliorate EAE. However, it must
be noted that the phenotype of the IL-9R KO mice is much
less robust than reported in IL-6 KO (Korn et al., 2007), IL-23
(p19 and p40) KO (Becher et al., 2002; Cua et al., 2003),
and RORt KO mice (Ivanov et al., 2006), which are completely protected from disease. Functionally, the data show
that disease in IL-9R KO mice correlates with a reduction of
IL-17A+ CD4 T cells and IL-6+ macrophages in the CNS of
mice, as well as a decrease in MC numbers in the lymph
nodes of mice. The later finding is not surprising, as IL-9 is
known as a growth and activation factor for MCs (Faulkner
et al., 1997; Townsend et al., 2000; Forbes et al., 2008). Extensive work performed by Melissa Brown’s group has also
shown that MC-deficient W/Wv mice display suboptimal
EAE (Secor et al., 2000; Tanzola et al., 2003; Gregory et al.,
2005), and we have observed a similar phenotype in MCdeficient Wsh mice (unpublished data).
The findings presented, in the context of the emerging
literature, establish that IL-9 cannot be readily assigned as being
either a pro- or antiinflammatory cytokine. Rather, its function may be as an autocrine differentiation factor for inflammatory T cells and/or T reg cells, or as a paracrine factor
regulating the activities of macrophages and/or MCs to mediate inflammation or suppression.
1657

Figure 4. IL-9R expression by both T cells and other cell types contributes to adoptively transferred EAE. (A and B) Lymphocytes from the
brains and spinal cords of WT (n = 4) and KO (n = 4) mice were isolated, counted, and stained for (A) CD4 T cells and IL-17A and (B) macrophages and
IL-6 after restimulation. The frequency of cytokine-producing cells by FACS was used to calculate the absolute numbers of cells shown. *, P < 0.01 by
the Student’s t test. Results show means ± SD and are representative of three independent experiments. (C) Peripheral lymph nodes of mice were pooled
and enriched for FCRI expression and stained for c-kit to identify MCs. Representative FACS plots are shown of WT and KO mice. Absolute numbers of
MCs in lymph nodes were determined for WT naive (n = 5), KO naive (n = 5), WT EAE (n = 12), and KO EAE (n = 14) mice pooled from four independent
experiments. A Student’s t test between the WT naive group and each other group was performed to assess statistical significance. Horizontal bars
represent means. (D) T cells from WT and KO mice with EAE were transferred to either WT or KO mice to cause disease. Mice were scored and the mean
disease scores ± SEM are shown. A Mann-Whitney U test was done to compare the WT T cell → WT group with each of the indicated groups to obtain
the p-values shown. Results were pooled from two independent experiments, and the numbers of mice used are as follows: WT T cell → WT, n = 16;
KO T cell → WT, n = 15; WT T cell → KO, n = 14; and KO T cell → KO, n = 12.

MATERIALS AND METHODS
Mice. C57BL/6 mice were purchased from Charles River Laboratories. IL-9R–
deficient mice (Steenwinckel et al., 2007) were provided by J.-C. Renauld
(Ludwig Institute, Brussels, Belgium) and were bred in-house. FoxP3-GFP
reporter mice were bred in-house after being provided by A. Rudensky
(University of Washington, Seattle, WA). Spleen cells from IL-17F–Thy1.1
reporter mice were provided by C.T. Weaver (University of Alabama at
Birmingham, Birmingham, AL) and have been previously described (Lee
et al., 2009). RORC-GFP mice (Ivanov et al., 2006) were purchased from
the Jackson Laboratory. All experiments using mice were performed in accordance with protocols approved by the Institutional Animal Care and Use
Committee of Dartmouth College.
EAE induction and clinical evaluation. Age-matched female
C57BL/6 and IL-9R KO mice that were 6–10 wk old were immunized
subcutaneously with 200 µg of MOG35-55 peptide (Peptides International)
1658

emulsified in CFA (Sigma-Aldrich) on day 0 and an i.p. injection of 400 ng
pertussis toxin (Sigma-Aldrich) on days 0 and 2. Mice were scored daily
as previously described (Becher et al., 2002). In some experiments, mice
were also treated with 200 µg of control Ig or IL-9 (MM9C1) antibody
(MedImmune) i.p. every other day starting the day before immunization.
For adoptively transferred EAE, T cells from WT and KO mice on day
14 after EAE induction were isolated and further cultured for 3 d in
vitro to promote Th17 cell differentiation, as previously described (Ogura
et al., 2008). Each mouse received 1.5–2 × 106 cells intravenously and 200
ng pertussis toxin on the day of the cell transfer and 7 d after the initial
immunization.
Histochemistry. Spinal cords from perfused mice with EAE were isolated.
Transverse sections of spinal cords (5-µm) were cut and stained with hematoxylin and eosin. Photographs of the sections were taken at 20× magnification using a microscope (BX41; Olympus).
IL-9, TH17, AND EAE | Nowak et al.

BRIEF DEFINITIVE REPORT

In vitro T cell differentiation. CD4+ CD25 FoxP3GFP cells were
cultured as previously described in RPMI 1640 to obtain Th1 and Th2 cells
(Lu et al., 2006). Th17 cells were generated with 2.5 ng/ml TGF-, 20 ng/ml
IL-6, 10 µg/ml IFN-, and 10 µg/ml IL-4 using 5 µg/ml of platebound CD3 (145-2C11; BioXCell) and CD28 (PV-1; BioXCell), respectively. For the differentiation of cells in the presence of TGF- and either
IL-2 or IL-4, all samples received 5 ng/ml TGF- with either 100 U/ml
IL-2 or 10 ng/ml IL-4.
qRT-PCR. RNA from various CD4 T cell subsets was isolated according
to the manufacturer’s directions using RNAeasy (QIAGEN). RNA was extracted from spinal cords, further treated with DNase using RNAqueous
(Applied Biosystems), and transcribed to cDNA using a cDNA synthesis kit
(iScript; Bio-Rad Laboratories). PCR was performed using iQ SYBR Green
Supermix (Bio-Rad Laboratories) on an iCycler (Bio-Rad Laboratories), as
previously described (Becher et al., 2002). All samples were normalized to
expression of GAPDH or -actin.
ELISAs and ELISPOTs. CD4 T cells from the draining lymph nodes of
EAE-immunized mice were isolated using a CD4+ selection kit (StemCell
Technologies Inc.). Cells were cultured in the presence of irradiated antigen-presenting cells and MOG peptide for 24 h. An IL-17A (eBioscience)
ELISPOT was performed with antibodies from the indicated manufacturer.
CD4 T cells from in vitro cultures were restimulated for the time indicated
in the figures before collection of supernatants. Splenic T cells from RORCGFP mice immunized with MOG emulsified in CFA were isolated 7 d later,
sorted on a FACSAria (BD), and recalled in vitro with PMA/ionomycin for
4 h. An IL-9 ELISA (PeproTech) was performed according to the manufacturer’s recommendations using duplicates or triplicates of each sample and a
standard curve of the recombinant cytokine.
Antibodies and reagents. Antibodies against the following were used for staining and, unless indicated otherwise, were obtained from BioLegend: CCR6-PE,
CD11b-FITC, CD11c-allophycocyanin (APC), CD4-PerCP, CD44-FITC and
-APC, CD45-A700, c-kit–A647, FCRI-PE (eBioscience), Thy1.1-PE (eBioscience), IL-6–PE, IL-17A–FITC and –APC, and IFN-–PE and –APC. AntiPE beads and LS columns were purchased from Miltenyi Biotec and used
according to the manufacturer’s directions to enrich for Thy1.1-PE+ T cells.
CNS lymphocyte isolation. Brains and spinal cords of perfused mice were
isolated as previously described (Becher et al., 2002). In brief, tissue was digested with DNase (Roche) and liberase (Roche), homogenized, and separated over a Percoll gradient before use.
MC enrichment. Lymph node cells were stained with c-kit–A647 and
FCRI-PE. Cells were enriched using anti-PE beads (StemCell Technologies Inc.) according to the manufacturer’s directions before being used for
FACS analysis. MC numbers were calculated as follows: MC numbers total
LN = (MC number in enriched sample) × (total number of cells in LN)/
(number of LN cells used at the start of enrichment).
Intracellular staining. For cytokine staining, cells were restimulated in vitro
for 5 h in the presence of 50 ng/ml PMA (EMD), 500 ng/ml ionomycin
(EMD), and 1 µl/ml monensin (BioLegend), followed by surface and intracellular cytokine staining according to the manufacturer’s directions (BD).
Graphs and statistics. All graphs were created and the indicated statistical
analysis was performed using Prism (GraphPad Software, Inc.).
Online supplemental material. Fig. S1 demonstrates ex vivo IL-9 production
by in vivo–generated Th17 cells from IL-17F reporter mice. Online supplemental material is available at http://www.jem.org/cgi/content/full/
jem.20090246/DC1.
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